You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

T-cell vaccine

Showing 76 - 100 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

COVID-19 Trial (Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C), Recombinant COVID-19

Not yet recruiting
  • COVID-19
  • Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)
  • Recombinant COVID-19 vaccine(Sf9 Cell) (WSK-V101)
  • (no location specified)
Jun 19, 2023

Immunosuppression, COVID-19 Trial in Madison (NVX-CoV2372)

Not yet recruiting
  • Immunosuppression
  • COVID-19
  • NVX-CoV2372
  • Madison, Wisconsin
    UW School of Medicine and Public Health
Aug 31, 2023

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Trial in

Active, not recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +11 more
  • Duarte, California
    City of Hope Medical Center
Dec 8, 2022

Circulating Tumor DNA Sequencing in Peripheral T-cell Lymphomas

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • circulating tumoral DNA detection
  • Rouen, France
    Centre Henri Becquerel
Oct 13, 2023

Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,

Recruiting
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Angioimmunoblastic T-cell Lymphoma
  • Changchun, Jilin, China
    The First Bethune Hospital of Jilin University
Apr 7, 2023

SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in

Recruiting
  • COVID-19
    • Baltimore, Maryland
    • +1 more
    Feb 2, 2023

    COVID-19 Trial (High dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell), Low dose of Recombinant

    Not yet recruiting
    • COVID-19
    • High dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)
    • +3 more
    • (no location specified)
    Jun 19, 2023

    T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)

    Not yet recruiting
    • T-Cell Non-Hodgkin Lymphoma
    • +14 more
    • WU-CART-007
    • Saint Louis, Missouri
      Washington University School of Medicine
    Jan 17, 2023

    Influenza, Human Trial in Brisbane (ARCT-2138, Licensed Quadrivalent Vaccine for younger adults, Licensed Quadrivalent Vaccine

    Not yet recruiting
    • Influenza, Human
    • ARCT-2138
    • +2 more
    • Brisbane, Queensland, Australia
      Nucleus Network Brisbane Clinic
    Nov 8, 2023

    Mantle Cell Lymphoma, Lymphoma, Mantle Cell Trial run by the NCI (EPOCH-R, GM-CSF, Idiotype vaccine)

    Completed
    Has Results
    • Mantle Cell Lymphoma
    • Lymphoma, Mantle Cell
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Jan 4, 2023

    Relapsed or Refractory T-cell Lymphomas Trial in Sendai-shi (BMS-986369)

    Not yet recruiting
    • Relapsed or Refractory T-cell Lymphomas
    • Sendai-shi, Miyagi, Japan
      Local Institution - 0001
    Sep 12, 2023

    Poliomyelitis Trial in Geelong, Melbourne (Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio), Inactivated

    Not yet recruiting
    • Poliomyelitis
    • Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio)
    • +3 more
    • Geelong, Victoria, Australia
    • +1 more
    Oct 30, 2023

    T-Cell and NK-Cell Tumor Trial

    Not yet recruiting
    • T-Cell and NK-Cell Neoplasm
      • (no location specified)
      Sep 28, 2023

      Vaccine Response Impaired Trial in Adelaide (BCG vaccine, Yellow Fever vaccine, Vancomycin Oral Capsule)

      Recruiting
      • Vaccine Response Impaired
      • BCG vaccine
      • +3 more
      • Adelaide, South Australia, Australia
        South Australian Health and Medical Research Institute
      Nov 17, 2023

      Metastatic Colorectal Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma Trial in

      Not yet recruiting
      • Metastatic Colorectal Adenocarcinoma
      • +5 more
      • Seattle, Washington
        Fred Hutch/University of Washington Cancer Consortium
      Sep 12, 2023

      NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen

      Not yet recruiting
      • NK-T-Cell Lymphoma, Extranodal
      • 4 cycles of ESA regimen with sandwiched radiotherapy
      • +2 more
      • Shanghai, Shanghai, China
        Ruijin Hospital
      Sep 29, 2023

      Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia Trial in Philadelphia (BEAM-201)

      Recruiting
      • Lymphoblastic Lymphoma
      • +2 more
      • BEAM-201
      • Philadelphia, Pennsylvania
        Children's Hospital of Philadelphia
      Jun 2, 2023

      NSCLC Trial in Ghent (Dendritic cell immunotherapy, Antigen-specific DTH, Control DTH)

      Active, not recruiting
      • Non-small Cell Lung Cancer
      • Dendritic cell immunotherapy
      • +2 more
      • Ghent, Belgium
        Ghent University Hospital
      Dec 23, 2022

      B Cell Malignancies Trial in Beijing, Shenzhen, Haikou (Universal CD19-specific CAR gene-engineered T cells)

      Recruiting
      • B Cell Malignancies
      • Universal CD19-specific CAR gene-engineered T cells
      • Beijing, Beijing, China
      • +2 more
      Aug 8, 2023

      Newly Diagnosed Peripheral T-cell Lymphoma Trial in Wuhan (Duvelisib, Chidamide)

      Recruiting
      • Newly Diagnosed Peripheral T-cell Lymphoma
      • Duvelisib, Chidamide
      • Wuhan, Hubei, China
        Union Hospital, Tongji Medical College, Huazhong University of S
      Jul 27, 2023

      Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal Cancer Trial in Shanghai (Fludarabine + Cyclophosphamide,

      Not yet recruiting
      • Cervical Cancer
      • +6 more
      • Fludarabine + Cyclophosphamide
      • HRYZ-T101 TCR-T Cell
      • Shanghai, Shanghai, China
        Fudan University Shanghai Cancer Center
      Mar 27, 2023

      Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V Trial in Beijing (KRAS-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

      Recruiting
      • Solid Tumor, Adult
      • +4 more
      • KRAS-EphA-2-CAR-DC
      • +3 more
      • Beijing, Beijing, China
        Biotherapeutic Department of Chinsese PLA Gereral Hospital
      Nov 29, 2022

      Pancreatic Ductal Adenocarcinoma, Refractory NSCLC Trial in Washington (Daratumumab, KRAS vaccine, Nivolumab)

      Not yet recruiting
      • Pancreatic Ductal Adenocarcinoma
      • Refractory Non-Small Cell Lung Cancer
      • Washington, District of Columbia
        Georgetown Lombardi Comprehensive Cancer Center
      Sep 1, 2023

      Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral Trial (SGN-35T)

      Not yet recruiting
      • Lymphoma, T-Cell, Cutaneous
      • +5 more
      • (no location specified)
      Nov 2, 2023

      HIV, Organ Transplantation, Lymphoma, Non-Hodgkin Trial in Melbourne (Pfizer Bivalent COVID-19 Vaccine, Moderna Bivalent mRNA

      Recruiting
      • HIV
      • +5 more
      • Pfizer Bivalent COVID-19 Vaccine
      • Moderna Bivalent mRNA vaccine
      • Melbourne, Victoria, Australia
        Alfred Health
      Jan 31, 2023